ARTICLES BY LOUIS

• Lentiviral Vectors And The Island Of Partnerships

  3/1/2023

  You need lentiviral vectors. Apparently, so do a lot of others. Demand for lentiviral vectors is estimated to surge at a compound annual growth rate (CAGR) of 11.4 % until 2032. I’ve learned of a location where you can grab some capacity – and related CGT services.

• Moderna And The Building Of Bridge Facilities

  2/27/2023

  In August of 2021, relatively overlooked because of other news swirling around our industry, Moderna became the anchor client in a new cleanroom on demand housed in a bridge facility in Massachusetts. In retrospect, it may have legitimized a new era in outsourcing.

• 6 CDMO Selection Tips From An Experienced Start-Up

  2/20/2023

  Does your process to select a CDMO emerge from within and without? Ryan Crisman, cofounder and Chief Technical Officer, Umoja Biopharma, Inc., says it should. And he's learned that from a wise consultant that became his full-time employee. Here are their 6 tips to successful CDMO partnerships.

• Building In Boulder – A Biotech Finds A Manufacturing Base

  2/13/2023

  If any of you have thoughts of building internal development and manufacturing facilities (to supplement or augment your outsourcing,) this is a discussion for you. It describes how on cell-therapy company made key decisions.

• A Bridge To Capacity For The Cell & Gene Industry

  2/8/2023

  Bridge facilities have been built for cell and gene therapy (CGT) sponsors – and CDMOs – to access here-and-now available, fully outfitted GxP capacity. But bring your own skilled workers. Here's how it works.

• Solving The Equation For A Cell Therapy Development Strategy

  2/3/2023

  Nowadays, “biotechs” emerge with unique business models, are hybrids of one kind or another, and operate as developers, platform/technology creators and service providers rolled up into one glorious organization. I found another one at Umoja Biopharma, Inc., a Seattle, Washington-based cell-therapy company. 

• Multiplying Forces Of Clinical Supply Outsourcing

  1/30/2023

  There are a number of varying and converging forces baring down on sponsors looking for CROs/CDMOs who can provide a full slate of services around their clinical-trial material. Both CDMOs and sponsors need to add or subtract from their strategies to adjust.

• CPHI Report Presents Shifting Outsourcing Realities

  1/24/2023

  While positive in tone, the 6th annual CPHI report demonstrates our outsourcing sands are indeed shifting. Which way for sponsors, CDMOs, and individual countries? Here's an analysis from our Chief Editor.

• CDMO Performance, The Workforce, And Reshoring

  1/19/2023

  There’s a broadening concern among U.S.-based drug and therapy developers regarding some of the challenges facing CDMOs in this country. Along with factors contributing to momentum for reshoring and investment in the U.S., we face some strong headwinds, including price and wage inflation.

• The Best CDMOs Are Redundant

  1/16/2023

  The top CDMO-selection criteria for Perry Calias, Chief Operations Officer, Revolo Biotherapeutics, and a veteran outsourcer, is redundancy. Redundancy laced with relationships, that is. Here's how it can work for you.